DTx EAST VIRTUAL

Former Managing Director at Opus Point Partners which created, financed, & operated 10+ science companies including Cougar Biotechnology (CGRB), Chelsea Therapeutics (CHTP), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Ziopharm Oncology (ZIOP)
Co-Founder & Owner at Klein Sun Gallery, America’s leading Chinese contemporary art gallery
Guest Lecturer, Biotechnology Program at Columbia University & 17+ years life science industry experience
Former Senior Consultant at Pfizer & Strategic Advisor at publicly traded & privately held life science companies
B.A., Brandeis University

Lesley Solomon, MBA, became Dana-Farber’s Senior Vice President and Chief Innovation Officer in 2017. She has served as the founding Executive Director of Brigham and Women’s Hospital’s Innovation Hub, and as Director of Strategy and Innovation at the Brigham Research Institute.

Lesley has more than 20 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her MBA from Harvard Business School and has a BA in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative at The Broad Institute of Harvard and MIT, which brings together experts across disciplines to unlock the biology of food allergy and change the field to develop new treatments and more.

Dr. Liz Kwo is an experienced healthcare executive with 15+ years specialized in building and scaling digital healthcare products to provide high quality care, leveraging predictive and prescriptive analytics to improve outcomes. Her current role at Anthem is to create digitized, automated, and continuously improved frictionless patient and provider experience that drives down cost of care. She has worked in remote patient monitoring for Medtronic, American Well as the VP of Provider Networks for telehealth, and is an active angel investor in the healthcare community, with a specific interest in technology-enabled healthcare delivery such as RubiconMD. She founded multiple venture-backed companies in educational technology (sold to CVC private equity firm in 2014), digital healthcare, and healthcare supplies and is passionate about creating seamless tailored experiences for enrolling patients and building on-demand data driven insights to support national employer clients.

Dr. Kwo has extensive experience in healthcare technology product development and commercialization, P&L, B2B/B2C marketing & sales, strategic partnerships, & post-merger integration. A practicing physician in urgent and preventive care, Dr. Kwo’s clinical expertise allows her to translate ideas from bench to bedside. She is also a lecturer in the Harvard-MIT HST Program and an Instructor of Medicine at Harvard Medical School.

Dr. Kwo has an MD from Harvard Medical School, MBA from Harvard Business School, MPH from Harvard TH Chan School of Public Health, and a BA from Stanford University. She completed her residency at Harvard Preventive Care and is Board Certified in Preventive Care and Occupational Medicine.

Kaia Health Inc. was founded with the aim to create evidence-based applications for self-management of chronic diseases to reflect the growing evidence of patient empowerment with effective therapies. Treatments which place patients in the driver’s seat of disease management and offer non-pharmacological alternatives are rapidly gaining importance in almost any chronic illness- from pain conditions to neurodegenerative diseases.

Kaia aims to create interdisciplinary digital approaches that empower patients to take control of the management of their diseases at low costs and to democratize access to required lifestyle changes following onset of a chronic disease. To achieve this, Kaia brings together experts in each of the medical fields in the creation of content and applications. This approach is paired with technological innovations to increase patient motivation, ensure correct exercise execution and monitor disease activity. Kaia’s first app democratizes the access to the multimodal back pain therapy. Pilot studies have consistently shown enduring pain reduction in users. This effect is currently being reproduced in RCTs. Kaia’s late stage pipeline ranges from COPD to osteoarthritis and Parkinson’s.

Konstantin is a serial entrepreneur. His last company foodora, a global food delivery company was sold to delivery hero in 2015. He now builds a digital therapeutics company called Kaia Health. He holds a dual Masters in Finance and Energy Systems from Columbia University and a Bachelor’s degree from Technical University

Lauren Li is Head of Digital Health at Ipsen, a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience, and Rare Diseases. Driven by a passion to improve the access to and quality of care around the world, she works at the intersection of life sciences and technology, leading a team to create “beyond the drug” solutions. Prior to Ipsen, she held multiple biotech commercial roles at Amgen both in the U.S. and in Europe, spanning digital innovation, analytics & insights, marketing, and sales. Lauren also formerly led strategy and operations at Princess Margaret Cancer Centre – a top 5 academic cancer hospital in the world, consulted at McKinsey & Company, and ran a successful family business. She holds an M.B.A. from Harvard Business School and a B.A. with honors in economics from Princeton University.

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Aaron Gani is the founder and CEO of BehaVR, LLC, creating digital therapeutics for behavioral health through the unmatched psychological power of Virtual Reality. Gani has been creating applications and experiences with technology throughout his career in healthcare and financial services, up to and including serving as Chief Technology Officer of Humana, a Fortune 50 managed care organization.

After a decade+ in healthcare leading technology development of population health, utilization management, disease management programs, pharmacy, primary care, urgent care, Health IT, and clinical analytics, and constantly working on ways to improve and empower consumer health with technology, data and analytics, Gani identified the crucial gap between knowledge, tools, and activation of healthy behavior, and believes Virtual Reality experiences can close that gap.

Gani is a founding member of the Strategic Advisory Board of the Digital Medicine (DiMe) Society, and a founding advisory board member of the International Virtual Reality Healthcare Association (IVRHA). Gani holds a Master’s in Predictive Analytics from Northwestern University, an MBA, General Management and Health Sector Management from Duke University’s Fuqua School of Business, and a BS in Management/CIS from the University of Louisville.

Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare.   She joined Boehringer Ingelheim Pharmaceuticals in 2008.  Within Boehringer Ingelheim Pharma, she worked across various regions and divisions.  She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast.  She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka.  In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate Development.  There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation.  She led  multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal.  Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA.   Debbie is a native Californian, she loves sunshine, being around nature and the ocean, yoga and dogs.

Dr. James is the Chief of Breast Surgical Oncology, co-Director of the Breast Care Center, and Vice Chair of Academic Affairs in the Department of Surgery at Beth Israel Deaconess Medical Center. His research interests focus on improving the quality of breast cancer surgery through outcomes research and clinical innovations. Dr. James provides research mentoring opportunities to medical students and residents.

In addition to his clinical background, Dr. James obtained a master’s degree in health care management from the Harvard School of Public Health and addresses health systems and quality issues in clinical oncology. He serves in national leadership roles and has directed programs in quality improvement, clinical education and health services research. His mission is to improve patient care through research, education and innovation.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.

Joris van Dam is a Digital Health intrapreneur with 15 years’ experience in Pharmaceutical Research & Development, focusing on the innovative use of digital technologies to improve and transform therapeutic innovation, patient engagement, and clinical trials operations. Joris is currently leading the Digital Therapeutics initiative at Novartis Institutes for BioMedical Research, including its collaboration with Pear Therapeutics on the development of therapies in schizophrenia and multiple sclerosis.

Prior to that, Joris launched a number of digital health innovation initiatives at Novartis, including the launch of the Trials of the Future program, the Patients-2-Trials Consortium (a pharma consortium project to facilitate clinical research navigation for patients), the Clinical Research Collaboration with Walgreens (running interventional clinical trials at local Walgreens Healthcare clinics), TriNetX (a platform for using electronic medical records for study planning and design), CentrosHealth (a platform for patient engagement Apps in clinical trials), and a mobile platform for bedside data collection for clinical trials in Africa.

Prior to joining Novartis, Joris spent 7 years at Janssen, where a.o. he worked in partnership with the Bill and Melinda Gates Foundation to launch a mobile health platform for improving treatment of HIV patients in various regions across India, and led Janssen’s participation to the EHR4CR program at the EU’s Innovative Medicines Initiative (IMI). Prior to joining pharmaceutical research and development, Joris spent 7 years in consulting across industries and across Europe. Joris holds a PhD in Artificial Intelligence from the University of Amsterdam.

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.

With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.

In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.

Jessica M. Lipschitz, Ph.D. is the Associate Director of the Digital Behavioral Health & Informatics Research Program at Brigham and Women’s Hospital and is affiliated with Harvard Medical School. Her research focuses on evaluation and implementation of digital behavioral health tools, specifically patient/provider/systems-level engagement and use of these tools to inform precision medicine. Dr. Lipschitz has worked extensively with the VA on national digital health rollout initiatives and has consulted and conducted research in partnership with industry aimed at improving and implementing digital health solutions for behavioral health. She serves on the editorial board for JMIR – Mental Health.

Madhavi Jagdish is the Director of Product Design at Pear Therapeutics, and has designed mobile applications for over a decade, both in the consumer space and now in this revolutionary field of prescription digital therapeutics. She is very excited about the possibility of design changing people’s lives in meaningful and long-lasting ways.

As Head of HappifyDTx and Board Member of the Digital Therapeutic Alliance (DTA), Chris is leading the effort to bring Happify’s platform to the pharmaceutical and healthcare industry. Recently he was a professor at the University of Utah and served as Executive Director of the Sorenson Center for Discovery & Innovation, a digital health game incubator. He is the co-author of two books on innovation, creativity, and leadership: Tension – The Energy of Innovation; and Solving for Why – Change Your Identity, Change Your Future. He is the named inventor on 12 issued patents, has been a founding leader in 10 startups, and has held leadership positions at JP Morgan and PwC. He holds a doctorate from George Washington University in Human and Organizational Learning, and an M.B.A. from UCLA Anderson School.

Sarah Jackson is Chief of Staff at Click Therapeutics, where she operates across business development, alliance management and strategy. In her role, Sarah actively seeks partnership and licensing opportunities, supports deal execution, and manages collaboration relationships and operations. Sarah holds a B.A. cum laude in Cognitive Neuroscience and Evolutionary Psychology from Harvard College.

Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas. Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business. In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device. Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business. She received an MSc from Waseda University and an MBA from Tsukuba University.

Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.

Pablo is Vice President and General Manager at Headspace Health. He leads the newly formed digital therapeutics subsidiary that aims to develop digital therapeutic products to help mitigate and treat chronic health conditions. Pablo also co-leads the Digital Health NEXT Program at Stanford Biodesign.

Before joining Headspace, Pablo was the Senior Director of Health and Venture Design at IDEO. He partnered with startups and global corporations alike to develop digital products and services at the intersection of health and other industries, such as mobility, retail and education.

Pablo is an entrepreneur. He co-founded Medtep, a digital health startup with the aim to facilitate lasting behavioral changes by personalizing validated prevention and treatment plans. While in college, Pablo founded his first start-up, Apartyment. Now part of Grupo Avanzia, the company helps international students in Europe to find accommodation, internships, and languages courses. Earlier in his career, Pablo worked as an economist for banks and brokerage firms, specializing in international markets.

Pablo was selected in the Forbes’ ‘30 Under 30’ list in healthcare in 2016. He is also an Endeavor entrepreneur and has mentored several other startups. Pablo holds a Master’s degree in Business Administration Technology from the Ramon Llull University, and a Bachelor’s degree in Economics and Business Administration from Pompeu Fabra University, both in Barcelona.

Malinda Peeples, MS, RN, CDE, FAADE is Senior Vice President of Clinical Services, Programs, and Research at WellDoc, a digital health company transforming the delivery of health care in the value-based world with the use of FDA-cleared digital health solutions focused on chronic disease care. In this role at WellDoc over the last decade Malinda has been a leader and champion in the digital health arena. She has been at the forefront of defining the digital health domain and remodeling how practitioners implement these clinically effective and cost containing innovative tools. By background Malinda is a registered nurse, certified diabetes educator and clinical and informatics nurse specialist.

Peeples earned a bachelor’s degree in nursing from the University of North Carolina in Charlotte, a master’s degree in nursing informatics from the University of Maryland School of Nursing (UMSON) in 1997, and a master’s degree in health sciences informatics from The Johns Hopkins School of Medicine in 2007. She currently serves as an Adjunct Assistant Faculty member in the Division of Healthcare Informatics at Johns Hopkins.

Malinda has been a dedicated volunteer for numerous local and national professional organizations. In 2005-2006 she served as President of the American Association of Diabetes Educators, an association that awarded the Distinguished Service Award to her in 2018. Currently Malinda is on the Maryland ADA Board of Directors and is on the University of Maryland at Baltimore Foundation Board of Trustees.

Brian is the co-founder and CEO of MedRhythms, Inc, a digital therapeutics company that builds evidence-based neurologic interventions for acute and chronic neurological populations using music, AI, and sensors.. As a clinician, Brian became one of only 2e50 people world with advanced training in the neuroscience of music. Harris was hired as the first NMT at Spaulding Rehabilitation Hospital in Boston, where, in 2015, he founded the clinical division of MedRhythms

As Chief Science Officer at SilverCloud health, Derek Richards is part of the executive team that decides on the strategic direction of the company and the execution of the strategic objectives for success. Over the past years, he has helped build a successful enterprise which gained significant market traction. Their success built on their robust empirical research base. As Chief Science Officer, Derek knows that a central aspect of where the organisation is going is the continued attention to research. They have a vigorous research strategy that supports the commercial strategy that they are committed to successfully realising.

As Director of the e-mental health group at the School of Psychology, Trinity College Dublin, Derek is involved in understanding how he and his team can leverage technologies to benefit mental health, health in general and our wellbeing. Digital health’s contribution to mental and behavioural healthcare has been significant, but they also know that we have most likely only begun to scratch the surface of the potential that current and emerging technologies can offer. It is a fascinating and innovative time for psychological science as it embraces technology to support the dissemination and greater access and reach to evidence-based treatments, preventative programmes and for the first time the potential to globalise these efforts. In collaboration with our partners, they are exploring many new avenues of implementation and research using online delivered interventions.

Eddie is CEO/co-founder of Akili Interactive, a leading digital therapeutics company creating treatments for people living with cognitive impairments. Akili was founded on the belief that medicine should not just be safe and effective, but fun and engaging. Akili’s products are delivered through immersive action video game experiences and the company is working to transform the patient experience. Prior to starting Akili in 2011, Eddie co-founded two other health-focused start-ups and helped to launch PureTech Health’s DH initiative. He is a former Kauffman Entrepreneur Fellow, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry and received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University. Eddie frequently serves on discussion panels for industry and academic events and appears in top-tier media reports on healthcare innovation. Akili has received recognition including the 2014 Future of Health Tech product award, 2015 50-on-Fire Boston, #1 health company in Entrepreneur magazine’s 100 Brilliant Companies of 2016, CNS Summit 2017 Innovation Award winner, and finalist for 2018 Bostonfest Coolest Companies and 2018 Business Intelligence Best Places to Work.

Patty Scalzo, MSN, NP, CDCES, is the Director of Diabetes Technology Initiatives at ADCES. In this role, she provides thought leadership, strategic direction and content expertise to ADCES’s Danatech platform and related resources. The Danatech platform was created to serve as the go to diabetes technology resource for the association membership of diabetes care and education specialists.

During her years at Mayo Clinic, Patty was co-recipient of an award through the Center for Innovation, to create a Diabetes Technology Clinic Remote Access program and to redesign the Diabetes Technology Clinic. Patty has experience in the medical device industry, digital health and clinical care.

Dr. Marisa Cruz is the Chief Medical Officer for Limbix. She previously served as the Senior Medical Advisor for the Digital Health Unit in the Center for Devices and Radiological Health at the US Food and Drug Administration, providing leadership in the development and implementation of digital health policy for medical devices. Prior to joining CDRH, Marisa served as a senior advisor to the Associate Commissioner for Public Health Strategy and Analysis. She received her M.D. from the Johns Hopkins School of Medicine, completed an Internal Medicine residency and Endocrinology fellowship at the University of California, San Francisco, and continues to provide clinical care at George Washington University.

Burt Rosen oversees all Marketing for HealthSparq.  He is responsible for developing and telling HealthSparq’s story; what we do, who we do it for and how we do it. He is passionate about putting people at the center of health care and has launched efforts such as What’s the Fix? to put people back in the center of the conversation.

Prior to HealthSparq, Burt spent five years at Knowledge Universe, the leading provider of early childhood education in the US (KinderCare is their biggest brand). He started there as VP Digital and Customer Experience and eventually took on all of Marketing, from market and customer research, to creative, PR, acquisition and everything digital.

Before Knowledge Universe, Burt was at Starwood Hotels for 4 years leading a digital and call center strategy team that serviced each of Starwood’s 9 brands, and eventually leading all marketing for Starwood Preferred Guest, Starwood’s award winning loyalty program.

Burt has 6 years of experience working in Account Management at Avenue A/Razorfish and Modem Media and 12 years experience working in all facets of Television on the advertising sales side.

Gregory Dodell, MD FACE is a board-certified endocrinologist. He received his medical degree from Albany Medical College. He completed his internal medicine and endocrinology Fellowship at St. Luke’s-Roosevelt Hospital Center, affiliated with Columbia University. He is an Assistant Clinical Professor of Medicine, Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai. He is the President of Central Park Endocrinology, PC.

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

Joanna Mitri, MD, MS, is interested in lifestyle-based interventions and prevention and management of type 2 diabetes and cardiometabolic disease.

Dr. Mitri practiced in Southern Massachusetts for few years prior to joining Joslin Diabetes Center.  Her clinical practice focuses on type 2 diabetes, lipid disorders and cardiovascular risk reduction. Her research has focused on the effect of lifestyle-based interventions in diabetes.

Dr. Mitri has published in several peer review journals on this topic.

Jen Horonjeff, PhD, is the founder and CEO of Savvy Cooperative, the first and only patient-owned public benefit co-op that helps healthcare companies connect directly with diverse patients in order to get the insights they need to build better and more inclusive innovations. Jen was named one of the 50 Most Daring Entrepreneurs of 2018 by Entrepreneur Magazine, alongside the likes of Elon Musk, Chance the Rapper and Reese Witherspoon, for her application of the cooperative model. Savvy has additionally won seven awards, and has been featured in Fast Company and the Boston Globe. Jen grew up with juvenile idiopathic arthritis and survived a brain tumor as an adult. She is also a health outcomes researcher at Columbia University Medical Center, a human factors engineer, and an FDA Consumer Representative. Jen earned her Master’s in Ergonomics and Biomechanics and PhD in Environmental Medicine, both from New York University. Utilizing her unique perspective, Jen is a sought after thought leader on patient engagement around the globe. She strives to give patients a platform to have their voices and expertise be heard, included, and equitably valued–because the future of healthcare is co-designed with patients.
Connect

Vik Panda is Dreem’s Managing Director for North America, where he spearheads the business across the healthcare industry and consumers. He launched Dreem 2 in the United States, which is a sleep solution that helps people improve the quality of their sleep through a wearable and coaching program. Dreem’s mission is to solve the world’s sleep problems and bring awareness to the importance of sleep. Before joining Dreem, Vik was VP of Marketing at Adherium, a digital therapeutic focused on asthma and COPD, where he launched a direct-to-consumer channel and developed the enterprise strategy. Prior to this, he was CEO at Findyr, an alternative data company, and Chief Marketing Officer at Fitocracy, a fitness social network and online coaching platform with more than 2 million users. Vik began his career in technology by pioneering solutions to help people get fit and healthy. He is a contributor to various outlets, including STAT, CNBC and MedCity News. He has a Master of Business Administration from INSEAD, a Bachelor of Arts and Master of Arts in Economics from New York University, and has completed the Chartered Financial Analyst program.

Martha Menard is a research scientist with 15+ of experience designing and leading research and evaluation projects for businesses, nonprofits, and academic institutions, specializing in integrative and behavioral health. She has her PhD in Research, Statistics and Evaluation from the University of Virginia, as well as having run a successful private massage therapy practice for over a decade.

Mr. Winder has over 25 years of operating, startup, and investing experience in healthcare companies. He plays an instrumental role in sourcing and structuring deals and works closely with portfolio companies to form strategic partnerships and to develop scalable commercialization and marketing strategies. He is currently (or formerly) Board Director or Observer at Aileron Therapeutics (IPO), AristaMD, Aventura (acquired by Philips Medical), Ayogo Health, ClearDATA, Cleveland HeartLab (acquired by Quest Diagnostics) InfoBionic, Laudio, Molecular Templates (IPO), Oculus Health, ShapeUp (merged with Virgin Pulse, acquired by Marlin), Silvercloud Health, Saladax Biomedical, Twistle, MedVentive (acquired by McKesson), and WellDoc.

Prior to joining MCIF, Mr. Winder was (and remains) Managing Director at Excel Venture Management. Prior to Excel Venture, Mr. Winder was a Principal at Biotechonomy Ventures where he was involved in the founding of Synthetic Genomics, serving as the Director of Finance, and its investments in BioTrove (acquired by Life Technologies), BIOCIUS (acquired by Agilent Technologies), and Xcellerex (acquired by GE Healthcare).

Prior to becoming a venture capitalist, Mr. Winder was an award-winning sales and marketing executive at medical equipment and diagnostics companies, Midmark Corporation and MGC Diagnostics. He graduated magna cum laude with an MBA from Babson College, where he was a Fellow in the Center for Technology Enterprise. He received a BA in Biology with a minor in Economics from Colby College.

Zack Lynch is a Managing Partner and co-founder of JAZZ Venture Partners, a San Francisco-based early stage venture capital firm focused on investing in human performance technology. He is an entrepreneur and futurist who brings a rich understanding of the forces driving the convergence of digital technologies and neuroscience and how new products and services are emerging to unlock human potential across health, wellness, learning, training, sports, enterprise and entertainment. He is the author of the best selling book The Neuro Revolution: How Brain Science Is Changing our World (St. Martin’s Press) which takes a 50 year view on how neuroscience will transform human society. Zack loves to snow board and spend time with his wife and kids.

Kate Rosenbluth is a Founder, Member of the Board of Directors, and Chief Scientific Officer at Cala Health. She has previously served as Chief Executive Officer and raised three rounds of financing totaling over $80M. She is an engineer and neuroscientist who previously worked on cutting edge neurotherapies at Stanford Biodesign, UCSF Neurosurgery, Brainlab, Autonomic Technologies and Genentech.

Mette Dyhrberg is a digital health innovator committed to improving the quality of life for those with chronic disease. She is the founder and CEO of Mymee, a digital program that is rethinking autoimmunity. The Mymee protocol eases the symptoms of autoimmune disease through data analytics and health coaching.  As an authority on autoimmune issues, Mette is a frequent speaker at industry events and conferences such as Stanford Medicine X and Exponential Medicine.

Mette holds MS in economics and is a certified health coach. An economist turned diagnostician, she’s the Sherlock Holmes of anamnestic data. She first entered the functional medicine arena in an attempt to tackle her own chronic health issues. In her early twenties, she became severely ill. For years, Mette battled an ever-expanding array of medical diagnoses ending up with six different autoimmune diseases simultaneously. Mette took matters into her own hands, hacked her own health and in doing so, she created a tool that solved her health problems and soon began helping others do the same.

Joe is the Chief Commercial Officer for Palo Alto Health Sciences, a digital therapeutic company that is focused in the behavior health space. Freespira is an FDA-cleared treatment  has been proven to significantly reduce or eliminate symptoms for patients suffering from panic attacks, Panic Disorder or PTSD. Prior to joining PAHS, Joe was the GM/SVP of North America for another start-up company in the behavioral space, called Brainsway, leading the company to successful IPO in 2019. He has a strong background in various sales and leadership roles in healthcare companies including St Jude Medical and Bristol-Myers Squibb. He earned his a BA from Penn State University and an MBA from Fordham University.

Dr. Kern is board certified in Addiction Medicine by the American Board of Addiction Medicine. In addition, she has been board certified by the American Board of Emergency Medicine. She is currently Global Medical Director at Pear Therapeutics, serving as an expert in Substance Use Disorder and Opioid Use Disorder for the development of clinically validated software designed to provide better outcomes for patients through Prescription Digital Therapeutics (PDTs), software-based disease treatments for SUD and OUD which are tested for safety and efficacy in randomized clinical trials, authorized by the FDA and prescribed by healthcare providers.

In addition to this work, she maintains a clinical practice at Sobriety Centers of New Hampshire, Antrim New Hampshire, treating a rural population of outpatients receiving medically assisted treatment for addiction disorders at a residential treatment facility for women.

Dr. Kern is an active leader within the American Society of Addiction Medicine (ASAM) and is Immediate Past President of the Northern New England Society of Addiction Medicine, representing Maine, New Hampshire and Vermont. She has made significant contributions to the field of addiction medicine. As Medical Director for the Addiction Research Center at Dartmouth, Dr. Kern was a leader in the design and coordination of NIH and industry sponsored multi-center trials at Dartmouth Hitchcock Medical Center with clinic sites in New Hampshire and throughout the country, with a focus on increasing treatment options for alcoholism. During her tenure at the Addiction Treatment Program at Dartmouth, she was a collaborating physician in the Vermont Medication Assisted Treatment Learning Collaborative, helping to pioneer the Hub and Spoke model of addiction health care delivery. As a member of the Perinatal Treatment Program, she provided specialized treatment for pregnant and postpartum women with substance use disorders. She has served in multiple leadership roles including Medical Director for the State of Vermont Department of Corrections, providing leadership and oversight in healthcare services for all inmates in the State of Vermont, and is a Certified Correctional Health Professional. Other roles have included Medical Director for Health Care Resource Centers, methadone treatment programs in New Hampshire, and the Road to a Better Life programs providing evaluation, coordination and ongoing care for addictions patients outpatient-based opioid treatment.

Dr. Kern earned her Medical Degree from New York Medical College in Valhalla NY and completed her Emergency Medicine residency at Albany Medical Center in Albany NY. She was the recipient of the Air Force Health Professions Scholarship and served in the United States Air Force from 1985 through 1997. She served as an Emergency Physician at Malcolm Grow Medical Center, Andrew Air Force Base, Washington D.C. and later at Walter Reed Army Hospital, and was a Clinical Instructor at the Uniformed Service University of Health Services in Bethesda, MD. She received the United States Air Force Medal for Meritorious Service.

Dr. Kern was awarded an Osherson Fellowship at the Alonso Center for Psychodynamics at the Fielding Graduate University in Santa Barbara, CA, where she completed a fellowship in 2013 with a study focus on psychodynamic research, theory and clinical application to the field of addictions.

Paul is a Senior Principal at Roche / Genentech where he leads the Smart Device Technology Center. Paul has 20 years of experience in medical device R&D, strategic marketing, product management, clinical research, and medical informatics.

Prior to Roche / Genentech, Paul was with Becton Dickinson(BD), as Worldwide Director of Strategic Marketing in their Pharmaceutical Systems business. Paul and his team were responsible for all upstream and downstream marketing strategy for BD’s self-injection business, including pen injectors, autoinjectors, and wearable patch injectors.

Prior to that role, Paul was with WellDoc, Inc as Director of Product Marketing, where he built and led the marketing team and was responsible for product management activities for WellDoc’s portfolio of mobile health solutions. He was also the Core Team Leader for WellDoc’s landmark BlueStar™ product, a class II medical device and the world’s first reimbursed, prescription-only software for type 2 diabetes.

Paul’s prior experience includes 10 years at BD in the Diabetes Care business. Paul was responsible for the development and launch of the award-winning BD InterActiv® Diabetes Software, and was a member of the joint BD / Medtronic core team that launched ParadigmLink®, the world’s first wireless blood glucose meter.

Paul holds an issued patent in medical software and numerous patent applications covering software and medical devices. He is also an author and co-author of numerous peer-reviewed articles in medical informatics and in diabetes. His education background includes undergraduate studies in cognitive science and graduate work in health informatics and finance at the University of Minnesota and New York University.

April Scott is Head of Patient Support at Akili Interactive. In this role, she is responsible for building and leading Akili’s personalized customer support services, Akili Assist.

Akili Assist strives to build meaningful and personalized relationships with every patient and their care teams however it’s easiest for them — by phone, via chat, text, or email. Akili Assist is the engine that enables Akili to do this by wrapping the care team around the patient experience.

Previously, April was the Director of Reimbursement Strategy and Patient Access at Otsuka America Pharmaceuticals where she provided oversight and strategic vision for the ASSURE Patient Support Center and the Otsuka Patient Assistance Foundation supporting multiple CNS and renal therapies. Specifically, April focused on transitioning the programs from traditional cookie-cutter solutions to those that met patients’ needs based on their individual journeys. Additionally, April was the Director of Assistance Programs at Mallinckrodt Pharmaceutical Inc.

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.

He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals.

Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Mr. Kellogg has worked in the medical device life-science industry for over 27 years and is currently the SVP in charge of medical devices (including RA, QA, GMP, and Clin Ops) at Akili Interactive Labs, Inc. Prior to joining Akili, Mr. Kellogg was an integral member of the founding teams at Follica Bio, Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., where he served as the Vice President of Business Operations, Vice President of Product Development, Vice President of R&D, and Director of Engineering, respectively.

In these leadership roles, Mr. Kellogg was focused on commercializing novel medical technology. The technologies included digital therapy, surgical modalities, transdermal analyte detection, point-of-care diagnostics, transdermal drug delivery, neuro-stimulation, and therapeutic drug/device combinations. Additionally, he served in lead project management roles at Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc (J&J). His broad experience includes product development/engineering, regulatory strategy/oversight, clinical design/operations, GMP & QSR establishment/compliance, intellectual property, and business development/strategic partnerships.

Mr. Kellogg graduated with high honors from the University of Massachusetts at Amherst with a BS in Engineering and received his MS and MBA from Northeastern University. He is an inventor on many domestic and international patents and the lead inventor on key patents for the Harmonic Scalpel ($1B/year product). In 2004 he and his team were awarded Popular Science’s “Best of what’s new in health care.”

Rachel Sha is the Vice President of Digital Business Development & Licensing at Sanofi.  She leads a team of

business development professionals in partnering, from identification to closing, across therapeutic areas and use cases in digital health with the goal of discovering, developing, and bringing to market solutions that improve outcomes, experience, at reduced costs.  Companies she has led partnering deals with in digital include Verily Life Sciences, Science 37, and Evidation Health.  Additionally, she serves on the Life Sciences Council of Springboard Enterprises which is focused on supporting women-led companies to grow and expand.

She joined Genzyme in 2005 and has held roles of increasing responsibility in Business Development, Corporate Development, and Global Marketing & Strategy for Genzyme and Sanofi.   Prior to Sanofi, Genzyme, Rachel was a manager at Accenture where she focused on a broad range of business issues from strategy to process to technology implementation.  Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-evaluated digital therapeutics into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Rochelle is VP, Client Success at Palo Alto Health Sciences, which offers Freespira, an FDA-cleared home-based and medication-free treatment that significantly reduces or eliminates symptoms of panic attacks, Panic Disorder and PTSD. Rochelle has decades of healthcare experience in a variety of roles including management consulting, health plan and employer sales, customer success, and marketing. Prior to joining the PAHS team, she worked for Best Doctors, Anthem, Towers Watson, Matria and NaviMedix. Rochelle received a Bachelor of Science degree from Kalamazoo College and a Masters in Social Work from the University of Michigan.

Andy gained his doctorate in psychology from the University of St Andrews before working as a medical research scientist in world-leading laboratories in the departments of psychiatry and experimental psychology at the University of Cambridge.

In 2006 he became Chief Scientific Officer of Cambridge Cognition, a psychology and technology-focused business, and a year later joined the company board. He was part of the team that developed the commercial strategy that built the company up to a successful public listing on the AIM market in 2013.

At Ieso Digital Health Andy’s principle role is to develop and implement a global science and technology strategy to complement the commercial vision of the company.

Lindsey Miller Santiago was born, raised, and currently lives in the Boston, MA area with her husband and 4-year-old son. She graduated from Babson College with a degree in marketing and entrepreneurship and started at ACP as a development associate in the summer of 2012. Her mission is to see a cure for MS in her lifetime, and believes that it will be possible because of the work ACP is doing!